NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, UBX shares have increased by 66.2% and is now trading at $8.96. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unity Biotechnology.

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Unity Biotechnology.

Unity Biotechnology Inc (NASDAQ:UBX) released its earnings results on Thursday, May, 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.03. View Unity Biotechnology's earnings history.

3 analysts have issued 1-year price objectives for Unity Biotechnology's shares. Their forecasts range from $13.00 to $33.00. On average, they anticipate Unity Biotechnology's stock price to reach $22.00 in the next year. This suggests a possible upside of 145.5% from the stock's current price. View analysts' price targets for Unity Biotechnology.

Media headlines about UBX stock have been trending negative on Sunday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Unity Biotechnology earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View the latest news about Unity Biotechnology.

Unity Biotechnology saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,670,000 shares, an increase of 8.1% from the June 15th total of 4,320,000 shares. Based on an average trading volume of 288,500 shares, the days-to-cover ratio is currently 16.2 days. Currently, 18.6% of the company's shares are short sold. View Unity Biotechnology's Current Options Chain.

Some companies that are related to Unity Biotechnology include Aurinia Pharmaceuticals (AUPH), CENTRIC HEALTH (CHH), SpringWorks Therapeutics (SWTX), USANA Health Sciences (USNA), Madrigal Pharmaceuticals (MDGL), Passage Bio (ZNTL), Glaukos (GKOS), Akebia Therapeutics (AKBA), Editas Medicine (EDIT), INDIVIOR PLC/S (INVVY), I-Mab (IMAB), Adverum Biotechnologies (ADVM), Y-mAbs Therapeutics (YMAB), Polynovo (PNV) and Zymeworks (ZYME). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), NIO (NIO), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD).

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of UBX stock can currently be purchased for approximately $8.96.

Unity Biotechnology has a market capitalization of $440.29 million. Unity Biotechnology employs 94 workers across the globe.